Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr129 Inhibitors

Olr129 inhibitors are a specialized class of chemical compounds designed to target and inhibit the Olr129 receptor, an olfactory receptor that is part of the extensive G protein-coupled receptor (GPCR) superfamily. These receptors are integral to the olfactory system, which is responsible for detecting and processing odorant molecules, leading to the perception of smells. Olr129 inhibitors function by binding to the receptor's active site, where natural odorant molecules would typically bind, or to other critical regions of the receptor that influence its activity. This binding effectively blocks the receptor from interacting with its natural ligands, preventing the conformational changes necessary for activating intracellular signaling pathways. By inhibiting these processes, Olr129 inhibitors disrupt the receptor's ability to transmit olfactory signals, thereby interfering with the normal function of the olfactory system. The development and design of these inhibitors are often based on detailed structural studies of the Olr129 receptor, utilizing advanced techniques such as X-ray crystallography, molecular modeling, and cryo-electron microscopy. These studies provide valuable insights into the receptor's binding sites and other functional regions, allowing for the creation of inhibitors that are highly specific and effective.

Chemically, Olr129 inhibitors exhibit a diverse array of structures and properties, reflecting the different synthetic strategies used in their development. These compounds can range from small, lipophilic molecules that easily penetrate cellular membranes to reach their target receptors, to larger, more complex molecules that may require sophisticated synthetic methods to optimize their binding affinity and specificity. The synthetic pathways for creating Olr129 inhibitors often involve multiple steps of organic chemistry, including the strategic formation of molecular frameworks and the incorporation of functional groups that enhance the inhibitor's interaction with the receptor. Once synthesized, these compounds are rigorously characterized using a variety of analytical techniques, such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and high-performance liquid chromatography (HPLC). These techniques are employed to confirm the structural integrity, purity, and inhibitory potency of the compounds. The study of Olr129 inhibitors is crucial for advancing our understanding of the specific mechanisms by which this olfactory receptor operates and how its activity can be modulated by small molecules. Furthermore, this research contributes to the broader field of GPCR biology, offering important insights into the molecular processes underlying sensory perception, particularly in the context of olfaction. By deepening our knowledge of how olfactory receptors function and how they can be selectively targeted, scientists can explore new avenues in the study of sensory systems and the complex biochemical pathways that govern them.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Pazopanib

444731-52-6sc-396318
sc-396318A
25 mg
50 mg
$130.00
$182.00
2
(1)

Multi-kinase inhibitor, might modulate signaling pathways relevant to Olr129's function.

Everolimus

159351-69-6sc-218452
sc-218452A
5 mg
50 mg
$131.00
$651.00
7
(1)

mTOR inhibitor, potentially affects cell growth pathways involving Olr129.

Regorafenib

755037-03-7sc-477163
sc-477163A
25 mg
50 mg
$320.00
$430.00
3
(0)

Multi-kinase inhibitor, could influence various signaling pathways affecting Olr129.

XL-184 free base

849217-68-1sc-364657
sc-364657A
5 mg
10 mg
$94.00
$208.00
1
(1)

MET and VEGFR2 inhibitor, may impact angiogenesis and pathways related to Olr129.

CH5424802

1256580-46-7sc-364461
sc-364461A
5 mg
50 mg
$191.00
$902.00
(0)

ALK inhibitor, potentially disrupts pathways Olr129 is involved in, altering its activity.

Osimertinib

1421373-65-0sc-507355
5 mg
$86.00
(0)

EGFR inhibitor, could disrupt growth factor signaling pathways involving Olr129.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

Bruton's tyrosine kinase inhibitor, might modulate cell signaling pathways relevant to Olr129.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$118.00
$337.00
$520.00
$832.00
$1632.00
10
(0)

BCL-2 inhibitor, may influence apoptosis pathways potentially linked to Olr129.

Nilotinib

641571-10-0sc-202245
sc-202245A
10 mg
25 mg
$209.00
$413.00
9
(1)

BCR-ABL inhibitor, could affect signaling pathways related to Olr129's function.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

CDK4/6 inhibitor, potentially affects cell cycle regulation pathways involving Olr129.